Is PRM or GDR more profitable?

Proteome Sciences has a net margin of -61.46% compared to genedrive's net margin of -500.75%. Proteome Sciences' return on equity of 23.85% beat genedrive's return on equity. Company Net Margins Return on Equity Return on Assets Proteome Sciences -61.46% 23.85% -19.25% genedrive -500.75% -1,044.57% -74.09%

Is PRM or AGL more profitable?

Proteome Sciences has a net margin of -61.46% compared to ANGLE's net margin of -1,444.04%. Proteome Sciences' return on equity of 23.85% beat ANGLE's return on equity. Company Net Margins Return on Equity Return on Assets Proteome Sciences -61.46% 23.85% -19.25% ANGLE -1,444.04% -191.36% -29.89%

Does the media prefer PRM or AGL?

In the previous week, Proteome Sciences and Proteome Sciences both had 1 articles in the media. ANGLE's average media sentiment score of 0.75 beat Proteome Sciences' score of -0.71 indicating that ANGLE is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Proteome Sciences 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative ANGLE 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is VRCI or PRM more profitable?

Proteome Sciences has a net margin of -61.46% compared to Verici Dx's net margin of -223.60%. Proteome Sciences' return on equity of 23.85% beat Verici Dx's return on equity. Company Net Margins Return on Equity Return on Assets Verici Dx -223.60% -127.57% -26.14% Proteome Sciences -61.46% 23.85% -19.25%

Does the media favor VRCI or PRM?

In the previous week, Verici Dx and Verici Dx both had 1 articles in the media. Proteome Sciences' average media sentiment score of -0.71 beat Verici Dx's score of -1.58 indicating that Proteome Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verici Dx 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Very Negative Proteome Sciences 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Does the media prefer GENI or PRM?

In the previous week, GENinCode had 4 more articles in the media than Proteome Sciences. MarketBeat recorded 5 mentions for GENinCode and 1 mentions for Proteome Sciences. GENinCode's average media sentiment score of -0.31 beat Proteome Sciences' score of -0.71 indicating that GENinCode is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GENinCode 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Proteome Sciences 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Proteome Sciences (PRM) Competitors

GBX 1.21 -0.29 (-19.39%)

As of 10:01 AM Eastern

Compare

PRM vs. GDR, YGEN, AGL, VRCI, and GENI

Should you buy Proteome Sciences stock or one of its competitors? Proteome Sciences's main competitors and comparable companies include genedrive (GDR), Yourgene Health (YGEN), ANGLE (AGL), Verici Dx (VRCI), and GENinCode (GENI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Proteome Sciences compare to genedrive?

Proteome Sciences (LON:PRM) and genedrive (LON:GDR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

In the previous week, Proteome Sciences had 1 more articles in the media than genedrive. MarketBeat recorded 1 mentions for Proteome Sciences and 0 mentions for genedrive. genedrive's average media sentiment score of 0.00 beat Proteome Sciences' score of -0.71 indicating that genedrive is being referred to more favorably in the news media.

Company	Overall Sentiment
Proteome Sciences	Negative
genedrive	Neutral

Proteome Sciences has a beta of 0.157, meaning that its share price is 84% less volatile than the broader market. Comparatively, genedrive has a beta of 0.968, meaning that its share price is 3% less volatile than the broader market.

Proteome Sciences has higher revenue and earnings than genedrive. genedrive is trading at a lower price-to-earnings ratio than Proteome Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Proteome Sciences	£3.77M	1.13	-£4.08M	-£1.04	N/A
genedrive	£929K	20.51	-£21.22M	-£0.79	N/A

Proteome Sciences has a net margin of -61.46% compared to genedrive's net margin of -500.75%. Proteome Sciences' return on equity of 23.85% beat genedrive's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Proteome Sciences	-61.46%	23.85%	-19.25%
genedrive	-500.75%	-1,044.57%	-74.09%

0.0% of Proteome Sciences shares are held by institutional investors. Comparatively, 0.1% of genedrive shares are held by institutional investors. 36.7% of Proteome Sciences shares are held by insiders. Comparatively, 28.1% of genedrive shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Proteome Sciences beats genedrive on 8 of the 13 factors compared between the two stocks.

How does Proteome Sciences compare to Yourgene Health?

Yourgene Health (LON:YGEN) and Proteome Sciences (LON:PRM) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

Yourgene Health has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, Proteome Sciences has a beta of 0.157, suggesting that its stock price is 84% less volatile than the broader market.

23.3% of Yourgene Health shares are held by institutional investors. Comparatively, 0.0% of Proteome Sciences shares are held by institutional investors. 64.4% of Yourgene Health shares are held by company insiders. Comparatively, 36.7% of Proteome Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Proteome Sciences has lower revenue, but higher earnings than Yourgene Health. Proteome Sciences is trading at a lower price-to-earnings ratio than Yourgene Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yourgene Health	£29.67M	0.00	-£8.17M	-£0.01	N/A
Proteome Sciences	£3.77M	1.13	-£4.08M	-£1.04	N/A

In the previous week, Proteome Sciences had 1 more articles in the media than Yourgene Health. MarketBeat recorded 1 mentions for Proteome Sciences and 0 mentions for Yourgene Health. Yourgene Health's average media sentiment score of 0.00 beat Proteome Sciences' score of -0.71 indicating that Yourgene Health is being referred to more favorably in the media.

Company	Overall Sentiment
Yourgene Health	Neutral
Proteome Sciences	Negative

Yourgene Health has a net margin of -27.55% compared to Proteome Sciences' net margin of -61.46%. Proteome Sciences' return on equity of 23.85% beat Yourgene Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Yourgene Health	-27.55%	-27.06%	-6.71%
Proteome Sciences	-61.46%	23.85%	-19.25%

Summary

Yourgene Health beats Proteome Sciences on 8 of the 12 factors compared between the two stocks.

How does Proteome Sciences compare to ANGLE?

Proteome Sciences (LON:PRM) and ANGLE (LON:AGL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

0.0% of Proteome Sciences shares are held by institutional investors. Comparatively, 17.5% of ANGLE shares are held by institutional investors. 36.7% of Proteome Sciences shares are held by insiders. Comparatively, 2.7% of ANGLE shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Proteome Sciences has higher revenue and earnings than ANGLE. Proteome Sciences is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Proteome Sciences	£3.77M	1.13	-£4.08M	-£1.04	N/A
ANGLE	£2.62M	2.89	-£21.76M	-£4.80	N/A

Proteome Sciences has a net margin of -61.46% compared to ANGLE's net margin of -1,444.04%. Proteome Sciences' return on equity of 23.85% beat ANGLE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Proteome Sciences	-61.46%	23.85%	-19.25%
ANGLE	-1,444.04%	-191.36%	-29.89%

Proteome Sciences has a beta of 0.157, suggesting that its stock price is 84% less volatile than the broader market. Comparatively, ANGLE has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market.

In the previous week, Proteome Sciences and Proteome Sciences both had 1 articles in the media. ANGLE's average media sentiment score of 0.75 beat Proteome Sciences' score of -0.71 indicating that ANGLE is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Proteome Sciences	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
ANGLE	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Proteome Sciences beats ANGLE on 7 of the 12 factors compared between the two stocks.

How does Proteome Sciences compare to Verici Dx?

Verici Dx (LON:VRCI) and Proteome Sciences (LON:PRM) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

Proteome Sciences has higher revenue and earnings than Verici Dx. Proteome Sciences is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verici Dx	£3.66M	1.40	-£6.56M	-£0.90	N/A
Proteome Sciences	£3.77M	1.13	-£4.08M	-£1.04	N/A

15.9% of Verici Dx shares are held by institutional investors. Comparatively, 0.0% of Proteome Sciences shares are held by institutional investors. 1.2% of Verici Dx shares are held by insiders. Comparatively, 36.7% of Proteome Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Verici Dx has a beta of 1.222, suggesting that its stock price is 22% more volatile than the broader market. Comparatively, Proteome Sciences has a beta of 0.157, suggesting that its stock price is 84% less volatile than the broader market.

In the previous week, Verici Dx and Verici Dx both had 1 articles in the media. Proteome Sciences' average media sentiment score of -0.71 beat Verici Dx's score of -1.58 indicating that Proteome Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verici Dx	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Very Negative
Proteome Sciences	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Proteome Sciences has a net margin of -61.46% compared to Verici Dx's net margin of -223.60%. Proteome Sciences' return on equity of 23.85% beat Verici Dx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verici Dx	-223.60%	-127.57%	-26.14%
Proteome Sciences	-61.46%	23.85%	-19.25%

Summary

Proteome Sciences beats Verici Dx on 7 of the 12 factors compared between the two stocks.

How does Proteome Sciences compare to GENinCode?

GENinCode (LON:GENI) and Proteome Sciences (LON:PRM) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

Proteome Sciences has a net margin of -61.46% compared to GENinCode's net margin of -202.42%. Proteome Sciences' return on equity of 23.85% beat GENinCode's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GENinCode	-202.42%	-481.34%	-63.99%
Proteome Sciences	-61.46%	23.85%	-19.25%

Proteome Sciences has higher revenue and earnings than GENinCode. Proteome Sciences is trading at a lower price-to-earnings ratio than GENinCode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GENinCode	£3.08M	1.76	-£6.10M	-£2.08	N/A
Proteome Sciences	£3.77M	1.13	-£4.08M	-£1.04	N/A

GENinCode has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market. Comparatively, Proteome Sciences has a beta of 0.157, indicating that its share price is 84% less volatile than the broader market.

In the previous week, GENinCode had 4 more articles in the media than Proteome Sciences. MarketBeat recorded 5 mentions for GENinCode and 1 mentions for Proteome Sciences. GENinCode's average media sentiment score of -0.31 beat Proteome Sciences' score of -0.71 indicating that GENinCode is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GENinCode	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Proteome Sciences	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

11.4% of GENinCode shares are owned by institutional investors. Comparatively, 0.0% of Proteome Sciences shares are owned by institutional investors. 8.4% of GENinCode shares are owned by insiders. Comparatively, 36.7% of Proteome Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Proteome Sciences beats GENinCode on 7 of the 13 factors compared between the two stocks.

Get Proteome Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRM vs. The Competition

Export

Metric	Proteome Sciences	Life Sciences Tools & Services Industry	Healthcare Sector	LON Exchange
Market Cap	£4.24M	£10.79B	£7.14B	£2.81B
Dividend Yield	6.17%	1.45%	2.53%	6.26%
P/E Ratio	-1.16	32.96	274.32	366.69
Price / Sales	1.13	109.41	609.37	89,148.58
Price / Cash	3.73	27.32	27.22	27.89
Price / Book	-0.68	7.24	11.23	6.98
Net Income	-£4.08M	£57.48B	£3.49B	£5.89B
7 Day Performance	N/A	3.88%	-1.68%	-0.76%
1 Month Performance	-22.04%	10.61%	-5.97%	-1.14%
1 Year Performance	-35.81%	36.19%	8.11%	22.91%

Proteome Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRM Proteome Sciences	N/A	GBX 1.21 -19.4%	N/A	-20.4%	£4.24M	£3.77M	N/A	240	Gap Up
GDR genedrive	N/A	GBX 1.20 +1.7%	N/A	+393.6%	£19.19M	£929K	N/A	43
YGEN Yourgene Health	N/A	N/A	N/A	N/A	£16.43M	£29.67M	N/A	253
AGL ANGLE	N/A	GBX 2.35 -11.3%	N/A	-14.5%	£7.58M	£2.62M	N/A	650	Gap Up
VRCI Verici Dx	N/A	GBX 0.25 +19.0%	N/A	N/A	£5.72M	£3.66M	N/A	19	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:PRM) was last updated on 10/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Proteome Sciences (PRM) Competitors

PRM vs. GDR, YGEN, AGL, VRCI, and GENI

How does Proteome Sciences compare to genedrive?

Summary

How does Proteome Sciences compare to Yourgene Health?

Summary

How does Proteome Sciences compare to ANGLE?

Summary

How does Proteome Sciences compare to Verici Dx?

Summary

How does Proteome Sciences compare to GENinCode?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRM vs. The Competition

Proteome Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Proteome Sciences (PRM) Competitors

PRM vs. GDR, YGEN, AGL, VRCI, and GENI

How does Proteome Sciences compare to genedrive?

Does the media prefer PRM or GDR?

Which has more volatility & risk, PRM or GDR?

Which has higher valuation and earnings, PRM or GDR?

Is PRM or GDR more profitable?

Do institutionals & insiders have more ownership in PRM or GDR?

Summary

How does Proteome Sciences compare to Yourgene Health?

Which has more risk and volatility, YGEN or PRM?

Do institutionals & insiders hold more shares of YGEN or PRM?

Which has preferable earnings and valuation, YGEN or PRM?

Does the media refer more to YGEN or PRM?

Is YGEN or PRM more profitable?

Summary

How does Proteome Sciences compare to ANGLE?

Do institutionals and insiders have more ownership in PRM or AGL?

Which has higher earnings and valuation, PRM or AGL?

Is PRM or AGL more profitable?

Which has more volatility & risk, PRM or AGL?

Does the media prefer PRM or AGL?

Summary

How does Proteome Sciences compare to Verici Dx?

Which has better earnings & valuation, VRCI or PRM?

Do insiders and institutionals believe in VRCI or PRM?

Which has more volatility and risk, VRCI or PRM?

Does the media favor VRCI or PRM?

Is VRCI or PRM more profitable?

Summary

How does Proteome Sciences compare to GENinCode?

Is GENI or PRM more profitable?

Which has stronger earnings & valuation, GENI or PRM?

Which has more risk and volatility, GENI or PRM?

Does the media prefer GENI or PRM?

Do institutionals and insiders hold more shares of GENI or PRM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRM vs. The Competition

Proteome Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools